Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Avecilla ST, Boulad F, Yazdanbakhsh K, Sadelain M, Shi PA. Process and procedural adjustments to improve CD34+ collection efficiency of hematopoietic progenitor cell collections in sickle cell disease. Transfusion. 2021;61(9):2775-2781.

Gao J, Fu L, Lu X, Sukhanova M, Frankfurt O, Mohtashamian A, et al. Mast cell sarcoma transdifferentiated from clonally-related T-lymphoblastic leukemia upon acquisition of mutation and genetic complexity. Leuk Lymphoma. 2021:1-4.

Racine-Brzostek SE, Karbaschi M, Gaebler C, Klasse PJ, Yee J, Caskey M, et al. TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. medRxiv. 2021.

Chen C-, Chen B-, Wang Y, Curman P, Beilinson HA, Brecht RM, et al. Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activity is required for V(D)J recombination. J Exp Med. 2021;218(8).

Ghantous Y, Omar M, Broner EC, Agrawal N, Pearson AT, Rosenberg AJ, et al. A robust and interpretable gene signature for predicting the lymph node status of primary T1/T2 oral cavity squamous cell carcinoma. Int J Cancer. 2021.

Leo P, Chandramouli S, Farré X, Elliott R, Janowczyk A, Bera K, et al. Computationally Derived Cribriform Area Index from Prostate Cancer Hematoxylin and Eosin Images Is Associated with Biochemical Recurrence Following Radical Prostatectomy and Is Most Prognostic in Gleason Grade Group 2. Eur Urol Focus. 2021;7(4):722-732.

Conteduca V, Ku S-, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, et al. Author Correction: Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ Precis Oncol. 2021;5(1):84.

Kaeberlein M, Tyler JK. A new era for research into aging. Elife. 2021;10.

Geyer JT, Prakash S, Orazi A. B-cell neoplasms and Hodgkin lymphoma in the spleen. Semin Diagn Pathol. 2021;38(2):125-134.

Sun M, Schaap A, Robinson BD, Nanus DM, Tagawa ST. A case report of a patient with plasmacytoid urothelial cancer with significant response to HER2-targeting therapy and enfortumab vedotin. Am J Clin Exp Urol. 2021;9(5):390-396.